Table 3.
Risk of NAFLD Development According to Obesity Status at Baseline and Body Weight Variability
| Presence of NAFLD | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|
| Normal and low ASVW | 655 (9.2) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Normal and high ASVW | 1,078 (16.7) | 1.84 (1.65–2.04) | 1.81 (1.63–2.02) | 1.80 (1.61–2.01) |
| Obese and low ASVWa | 203 (38.3) | 3.94 (3.23–4.80) | 3.12 (2.55–3.83) | 2.77 (2.26–3.41) |
| Obese and high ASVW | 470 (37.5) | 4.44 (3.84–5.13) | 3.52 (3.03–4.09) | 3.11 (2.66–3.62) |
| Normal and low CV | 673 (9.8) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Normal and high CV | 1,060 (15.8) | 1.99 (1.79–2.22) | 2.05 (1.84–2.29) | 2.05 (1.84–2.29) |
| Obese and low CVa | 301 (36.2) | 3.45 (2.92–4.07) | 2.80 (2.36–3.33) | 2.50 (2.10–2.97) |
| Obese and high CV | 372 (39.1) | 5.36 (4.57–6.28) | 4.27 (3.62–5.03) | 3.76 (3.18–4.44) |
Values are expressed as number (%) or odds ratio (95% confidence interval). Model 1: Adjusted for age and sex; Model 2: Adjusted for Model 1+fasting blood glucose, systolic blood pressure, triglyceride, low-density lipoprotein cholesterol, smoking status, exercise, and alcohol intake; Model 3: Adjusted for Model 2+homeostatic model assessment of insulin resistance, glycated hemoglobin, aspartate transaminase.
NAFLD, nonalcoholic fatty liver disease; ASVW, average successive variability of weight; CV, coefficient of variation.
a
Body mass index cut off of 25 kg/m2 was used to define obesity in the Korean population in this study.